The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Safety and pharmacodynamics of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration.
 
Mark N. Stein
Research Funding - Abbvie (Inst); Advaxis (Inst); Astellas Pharma (Inst); Bavarian Nordic (Inst); Janssen Oncology (Inst); Medivation/Astellas (Inst); Merck Sharp & Dohme (Inst); Oncoceutics (Inst); Suzhou Kintor Pharmaceuticals (Inst); Suzhou Kintor Pharmaceuticals (Inst)
 
Jyoti Malhotra
Consulting or Advisory Role - AstraZeneca; Pfizer
 
Usha Malhotra
No Relationships to Disclose
 
Ann W. Silk
Research Funding - Amgen (Inst); Bristol-Myers Squibb (Inst); Merck (Inst); Prometheus (Inst); Viralytics (Inst)
 
Nancy Chan
No Relationships to Disclose
 
Lorna Rodriguez-Rodriguez
No Relationships to Disclose
 
Joseph Aisner
Honoraria - Ethicon
Consulting or Advisory Role - Bristol-Myers Squibb; EMD Serono
 
Robert Aiken
No Relationships to Disclose
 
Jenna Newman
No Relationships to Disclose
 
Evita Sadimin
No Relationships to Disclose
 
Tracie Saunders
No Relationships to Disclose
 
Melissa Frankel
No Relationships to Disclose
 
Aparna Kareddula
No Relationships to Disclose
 
Wafik S. El-Deiry
Stock and Other Ownership Interests - Oncoceutics; p53-Therapeutics
Research Funding - Bayer; Loxo; Morphotek; Tarmeta Biosciences
Patents, Royalties, Other Intellectual Property - Patent on TIC10 (ONC201); Patents pending on the use of small molecules to target mutant p53
Other Relationship - Caris Life Sciences
 
Rohinton Tarapore
No Relationships to Disclose
 
Joshua E. Allen
Employment - Oncoceutics
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
 
Joseph R. Bertino
Stock and Other Ownership Interests - Oncoceutics
Research Funding - Phosplatin Therapeutics
 
Steven K. Libutti
Stock and Other Ownership Interests - AAVP Biosystems
Patents, Royalties, Other Intellectual Property - National Cancer Institute
 
Janice M. Mehnert
Honoraria - EMD Serono; Genentech
Consulting or Advisory Role - Amgen; Boehringer Ingelheim; Merck Sharp & Dohme
Research Funding - Amgen (Inst); AstraZeneca (Inst); Immunocore (Inst); Incyte (Inst); macrogenics (Inst); macrogenics (Inst); Merck (Inst); Merck (Inst); Merck (Inst); Novartis (Inst); polynoma (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - EMD Serono; Merck Sharp & Dohme
Other Relationship - Amgen; Boehringer Ingelheim; EMD Serono; Merck; Merck
 
Andrew Zloza
Research Funding - FC Richardson Consulting; Merck Sharp & Dohme